ArticleInfection2026
Temporal trends in Group A Streptococcus epidemiology, antimicrobial susceptibility and emm-type distribution: a seven-year surveillance study from a UK district general hospital.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGroup A Streptococcus (GAS) remains universally susceptible to penicillin; however, resistance to macrolides and clindamycin varies geographically and may affect management, particularly in patients with penicillin allergy. Recent increases in GAS incidence reported in the United Kingdom highlight the need for continued local epidemiological and antimicrobial resistance surveillance.
methodsWe conducted a retrospective laboratory-based surveillance study at a UK district general hospital between January 2017 and December 2023. All laboratory-confirmed GAS isolates were included. Isolates were classified as invasive or non-invasive based on specimen source. Antimicrobial susceptibility testing was performed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) methodology, and emm typing was undertaken for available invasive isolates. Data were analysed descriptively to assess temporal trends across pre-pandemic, pandemic and post-pandemic periods.
resultsA total of 2,893 GAS isolates were identified, including 45 invasive isolates (1.6%). GAS activity demonstrated marked temporal variation during the seven-year surveillance period, with substantial suppression during 2020-2021 followed by a marked increase in 2022-2023, exceeding pre-pandemic levels. Throat swab specimens accounted for the largest proportion of isolates (59.0%), followed by wound specimens (22.8%) and genital specimens (12.4%). Penicillin susceptibility remained universal throughout the study period. Erythromycin and clindamycin susceptibility demonstrated temporal variation, with the lowest susceptibility observed in 2021 before recovery in subsequent years. Tetracycline susceptibility remained relatively stable. Among typed invasive isolates (29/45), emm1 was the predominant emm type (48.3%).
conclusionsGAS activity demonstrated marked temporal variation, with a substantial increase following the COVID-19 pandemic. Despite this, antimicrobial susceptibility patterns remained largely stable, with universal penicillin susceptibility. Variability in macrolide and clindamycin susceptibility highlights the importance of ongoing surveillance to inform empirical therapy, particularly in penicillin-allergic patients. The predominance of emm1 among invasive isolates aligns with national trends and supports continued molecular surveillance.
Indexed as
Identifiers
42223843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.